Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Incyte Corporation - Common Stock (NQ:INCY)

60.91 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
From Genesis Therapeutics, Inc. and Incyte
Via Business Wire
NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced. 
Via Chartmill
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for. 
Via StockStory
What Analysts Are Saying About Incyte Stock
Via Benzinga
Insights into Incyte Q4 Earnings
Via Benzinga
NASDAQ:INCY, an undervalued stock with good fundamentals.
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
What's going on in today's pre-market session: S&P500 movers
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
Why Incyte (INCY) Shares Are Plunging Today
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.9% in the morning session after the company reported fourth-quarter results with full-year guidance for key products such as... 
Via StockStory
Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday?
Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
Via Benzinga
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Gapping S&P500 stocks in Monday's session
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches
Incyte projects 2025 Jakafi revenue of $2.925B-$2.975B, up 4.76%-6.55%, and Opzelura sales of $630M-$670M, reflecting up to 31.81% growth. 
Via Benzinga
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2024, with sales up 16.3% year on year to $1.18 billion. Its non-GAAP profit of $1.43 per share... 
Via StockStory
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
From Incyte
Via Business Wire
Earnings Scheduled For February 10, 2025
Via Benzinga
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect. 
Via StockStory
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Promising Signs: INCYTE CORP Setting the Stage for a Breakout.
Exploring INCYTE CORP's Technical Signals and Breakout Potential: Based on good technical signals, INCYTE CORP is potentially setting up for a breakout. 
Via Chartmill
Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents.
Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced. 
Via Chartmill
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
From Incyte
Via Business Wire
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline
Incyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets. 
Via Benzinga
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Via ACCESSWIRE
Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
Via ACCESSWIRE
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.